Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer's Disease

Shawn J. Stachel, Celina Zerbinatti, Michael T. Rudd, Mali Cosden, Sokreine Suon, Kausik K. Nanda, Keith Wessner, Jillian Dimuzio, Jill Maxwell, Zhenhua Wu, Jason M. Uslaner, Maria S. Michener, Peter Szczerba, Edward Brnardic, Vanessa Rada, Yuntae Kim, Robert Meissner, Peter Wuelfing, Yang Yuan, Jeanine BallardMarie Holahan, Daniel J. Klein, Jun Lu, Xavier Fradera, Gopal Parthasarathy, Victor N. Uebele, Zhongguo Chen, Yingjie Li, Jian Li, Andrew J. Cooke, D. Jonathan Bennett, Mark T. Bilodeau, John Renger

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Herein, we describe the development of a functionally selective liver X receptor β (LXRβ) agonist series optimized for Emax selectivity, solubility, and physical properties to allow efficacy and safety studies in vivo. Compound 9 showed central pharmacodynamic effects in rodent models, evidenced by statistically significant increases in apolipoprotein E (apoE) and ATP-binding cassette transporter levels in the brain, along with a greatly improved peripheral lipid safety profile when compared to those of full dual agonists. These findings were replicated by subchronic dosing studies in non-human primates, where cerebrospinal fluid levels of apoE and amyloid-β peptides were increased concomitantly with an improved peripheral lipid profile relative to that of nonselective compounds. These results suggest that optimization of LXR agonists for Emax selectivity may have the potential to circumvent the adverse lipid-related effects of hepatic LXR activity.

Original languageEnglish (US)
Pages (from-to)3489-3498
Number of pages10
JournalJournal of Medicinal Chemistry
Issue number7
StatePublished - Apr 28 2016
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this